Aquestive Therapeutics Taps Allergy Expert as CMO Ahead of Key FDA Resubmission
Event summary
- Aquestive Therapeutics appointed Dr. Matthew Greenhawt as Chief Medical Officer on February 18, 2026.
- Dr. Greenhawt is an internationally recognized allergist with expertise in food allergy, anaphylaxis, and patient-centered care.
- He previously served as Chief Medical Officer of the Asthma and Allergy Foundation of America (AAFA).
- Aquestive is preparing to resubmit its Anaphylm™ New Drug Application (NDA) to the FDA.
The big picture
Aquestive Therapeutics is strengthening its leadership team with the appointment of Dr. Matthew Greenhawt as Chief Medical Officer, a move aimed at bolstering its regulatory strategy ahead of the Anaphylm™ NDA resubmission. This appointment comes at a critical juncture for the company, as it seeks to address real-world challenges in epinephrine administration and differentiate its product in a competitive allergy treatment market. The strategic focus on patient-centered care and innovation aligns with broader industry trends towards more accessible and user-friendly emergency treatments.
What we're watching
- Regulatory Resubmission
- The pace at which Aquestive can address FDA concerns and secure approval for Anaphylm™ will determine its market entry timing.
- Pipeline Advancement
- Whether Dr. Greenhawt's expertise can accelerate the development of Aquestive's AdrenaVerse™ pipeline, including AQST-108 for dermatological indications.
- Market Differentiation
- How Aquestive positions Anaphylm™ against existing epinephrine treatments, leveraging its sublingual film technology to overcome barriers like needle anxiety.
Related topics